Skip to main content
Erschienen in: Osteoporosis International 3/2014

01.03.2014 | Original Article

Possible FRAX-based intervention thresholds for a cohort of Chinese postmenopausal women

verfasst von: E. Cheung, C.-L. Cheung, A. W. C. Kung, K. C. B. Tan

Erschienen in: Osteoporosis International | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Summary

A total of 2,266 postmenopausal Chinese women were followed for 4.5 years to determine the incidence of new fractures. The positive predictive value, negative predictive value, sensitivity and specificity of different treatment strategies were compared. Using a fixed optimal threshold calculated from receiver operating characteristics (ROC) curve had the highest sensitivity but lowest specificity.

Introduction

There is no specific intervention threshold based on FRAX to guide treatment for Asian populations. This prospective study sought to determine the impact of applying different intervention thresholds to a cohort of Chinese postmenopausal women.

Methods

This study was part of the Hong Kong Osteoporosis Study. A total of 2,266 treatment-naïve postmenopausal women underwent clinical risk factor and BMD assessments. The subjects were followed to assess fractures. We calculated the FRAX probability of major osteoporotic fractures corresponding to women with prior fractures but no other clinical risk factors. Different treatment strategies which include treating women with prior fractures, women with age-specific FRAX probability corresponding to those with prior fractures, women with osteoporosis as well as women with FRAX probability above a fixed cut-off based on optimizing sensitivity and specificity on the ROC curve were compared.

Results

The mean age at baseline was 62.1 ± 8.5 years, and the mean follow-up time was 4.5 ± 2.8 years. One hundred six new major osteoporotic fractures were reported. An optimal (FRAX, with BMD) cut-off point of 9.95 % was identified. All strategies had negative predictive value of >90 %. Using a fixed cut-off had the highest sensitivity (62.3 %) but lowest specificity (73.5 %) and positive predictive value (10.3 %). Using a fixed cut-off would direct treatment from younger women with lower absolute risk to elderly women with higher absolute risk.

Conclusion

Targeting only women with prior fractures is unlikely to reduce fracture burden. Other treatment strategies with higher sensitivity need to be considered but they have different shortcomings
Literatur
1.
Zurück zum Zitat Siris ES, Chen YT, Abbott TA et al (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164(10):1108–1112PubMedCrossRef Siris ES, Chen YT, Abbott TA et al (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164(10):1108–1112PubMedCrossRef
2.
Zurück zum Zitat Schuit SC, Van der Klift M, de Laet CE et al (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam study. Bone 34(1):195–202PubMedCrossRef Schuit SC, Van der Klift M, de Laet CE et al (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam study. Bone 34(1):195–202PubMedCrossRef
3.
Zurück zum Zitat Pasco JA, Seeman E, Henry MJ et al (2006) The population burden of fractures originates in women with osteopenia not osteoporosis. Osteoporos Int 17(9):1404–1409PubMedCrossRef Pasco JA, Seeman E, Henry MJ et al (2006) The population burden of fractures originates in women with osteopenia not osteoporosis. Osteoporos Int 17(9):1404–1409PubMedCrossRef
4.
Zurück zum Zitat Kanis JA, Oden A, Johnell O et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046PubMedCrossRef Kanis JA, Oden A, Johnell O et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033–1046PubMedCrossRef
6.
Zurück zum Zitat Nguyen ND, Frost SA, Center JR et al (2008) Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 19:1431–1444PubMedCrossRef Nguyen ND, Frost SA, Center JR et al (2008) Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 19:1431–1444PubMedCrossRef
7.
Zurück zum Zitat Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ 339:b4229PubMedCentralPubMedCrossRef Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ 339:b4229PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Cooper C, Melton LJ (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2:285–289PubMedCrossRef Cooper C, Melton LJ (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2:285–289PubMedCrossRef
10.
Zurück zum Zitat Kanis JA, McCloskey EV, Johansson H et al (2008) Case finding for the management of osteoporosis with FRAX—assessment and intervention thresholds for the UK. Osteoporos Int 19:1395–1408PubMedCrossRef Kanis JA, McCloskey EV, Johansson H et al (2008) Case finding for the management of osteoporosis with FRAX—assessment and intervention thresholds for the UK. Osteoporos Int 19:1395–1408PubMedCrossRef
11.
Zurück zum Zitat Compston J, Cooper A, Cooper C et al (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62:105–108PubMedCrossRef Compston J, Cooper A, Cooper C et al (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62:105–108PubMedCrossRef
12.
Zurück zum Zitat Briot K, Cortet B, Thomas T et al (2012) 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine 79:304–313PubMedCrossRef Briot K, Cortet B, Thomas T et al (2012) 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine 79:304–313PubMedCrossRef
13.
Zurück zum Zitat Kanis JA, McCloskey EV, Johansson H, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) et al (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24(1):23–57PubMedCentralPubMedCrossRef Kanis JA, McCloskey EV, Johansson H, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) et al (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24(1):23–57PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Orimo H, Hayashi Y, Fukunaga M et al (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337PubMedCrossRef Orimo H, Hayashi Y, Fukunaga M et al (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337PubMedCrossRef
15.
Zurück zum Zitat Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, National Osteoporosis Foundation Guide Committee et al (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19(4):437–447PubMedCentralPubMedCrossRef Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, National Osteoporosis Foundation Guide Committee et al (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19(4):437–447PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, National Osteoporosis Foundation Guide Committee et al (2008) Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 19(4):449–458PubMedCrossRef Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, National Osteoporosis Foundation Guide Committee et al (2008) Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 19(4):449–458PubMedCrossRef
17.
Zurück zum Zitat OSHK Task Group for Formulation of 2013 OSHK Guideline for Clinical Management of Postmenopausal Osteoporosis in Hong Kong, Ip I, Cheung SK, Cheung TC et al (2013) The Osteoporosis Society of Hong Kong (OSHK): 2013 OSHK guideline for clinical management of postmenopausal osteoporosis in Hong Kong. Hong Kong Med J 19(Suppl 2):1–40PubMed OSHK Task Group for Formulation of 2013 OSHK Guideline for Clinical Management of Postmenopausal Osteoporosis in Hong Kong, Ip I, Cheung SK, Cheung TC et al (2013) The Osteoporosis Society of Hong Kong (OSHK): 2013 OSHK guideline for clinical management of postmenopausal osteoporosis in Hong Kong. Hong Kong Med J 19(Suppl 2):1–40PubMed
18.
Zurück zum Zitat Cheung EY, Bow CH, Cheung CL et al (2012) Discriminative value of FRAX for fracture prediction in a cohort of Chinese postmenopausal women. Osteoporos Int 23(3):871–878PubMedCrossRef Cheung EY, Bow CH, Cheung CL et al (2012) Discriminative value of FRAX for fracture prediction in a cohort of Chinese postmenopausal women. Osteoporos Int 23(3):871–878PubMedCrossRef
19.
Zurück zum Zitat Bewick V, Cheek L, Ball J (2004) Statistics review 13: receiver operating characteristic curves. Crit Care 8(6):508–512PubMedCrossRef Bewick V, Cheek L, Ball J (2004) Statistics review 13: receiver operating characteristic curves. Crit Care 8(6):508–512PubMedCrossRef
21.
22.
Zurück zum Zitat Coffin M, Sukhatme S (1997) Receiver operating characteristic studies and measurement errors. Biometrics 53:823–837PubMedCrossRef Coffin M, Sukhatme S (1997) Receiver operating characteristic studies and measurement errors. Biometrics 53:823–837PubMedCrossRef
23.
Zurück zum Zitat Sharir T, Berman DS, Waechter PB et al (2001) Quantitative analysis of regional motion and thickening by gated myocardial perfusion SPECT: normal heterogeneity and criteria for abnormality. J Nucl Med 42:1630–1638PubMed Sharir T, Berman DS, Waechter PB et al (2001) Quantitative analysis of regional motion and thickening by gated myocardial perfusion SPECT: normal heterogeneity and criteria for abnormality. J Nucl Med 42:1630–1638PubMed
24.
Zurück zum Zitat Report of Hospital Authority, Hong Kong, 1996 Report of Hospital Authority, Hong Kong, 1996
25.
Zurück zum Zitat Lippuner K, Johansson H, Borgström F et al (2012) Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland. Osteoporos Int 23(11):2579–2589PubMedCrossRef Lippuner K, Johansson H, Borgström F et al (2012) Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland. Osteoporos Int 23(11):2579–2589PubMedCrossRef
26.
Zurück zum Zitat Lippuner K (2012) Osteoporosis—whom to treat? The importance of FRAX® in Switzerland. Ther Umsch 69(3):207–213PubMedCrossRef Lippuner K (2012) Osteoporosis—whom to treat? The importance of FRAX® in Switzerland. Ther Umsch 69(3):207–213PubMedCrossRef
27.
Zurück zum Zitat Bolland MJ, Grey A (2010) Disparate outcomes from applying U.K. and U.S. osteoporosis treatment guidelines. J Clin Endocrinol Metab 95(4):1856–1860PubMedCrossRef Bolland MJ, Grey A (2010) Disparate outcomes from applying U.K. and U.S. osteoporosis treatment guidelines. J Clin Endocrinol Metab 95(4):1856–1860PubMedCrossRef
28.
Zurück zum Zitat Orimo H, Nakamura T, Hosoi T et al (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary. Arch Osteoporos 7(1–2):3–20PubMedCentralPubMedCrossRef Orimo H, Nakamura T, Hosoi T et al (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary. Arch Osteoporos 7(1–2):3–20PubMedCentralPubMedCrossRef
29.
Zurück zum Zitat Fujiwara S, Nakamura T, Orimo H (2008) Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int 19(4):429–435PubMedCentralPubMedCrossRef Fujiwara S, Nakamura T, Orimo H (2008) Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int 19(4):429–435PubMedCentralPubMedCrossRef
30.
Zurück zum Zitat Kanis JA, Johansson H, Oden A et al (2012) The distribution of FRAX(®)-based probabilities in women from Japan. J Bone Miner Metab 30(6):700–705PubMedCrossRef Kanis JA, Johansson H, Oden A et al (2012) The distribution of FRAX(®)-based probabilities in women from Japan. J Bone Miner Metab 30(6):700–705PubMedCrossRef
31.
Zurück zum Zitat Committee for Medicinal Products for Human Use (CHMP) (2006) Guideline on the evaluation of Medicinal products in the treatment of primary osteoporosis. CHMP, London, Ref CPMP/EWP/552/95Rev.2. Nov 2006 Committee for Medicinal Products for Human Use (CHMP) (2006) Guideline on the evaluation of Medicinal products in the treatment of primary osteoporosis. CHMP, London, Ref CPMP/EWP/552/95Rev.2. Nov 2006
32.
Zurück zum Zitat Kanis JA, McCloskey E, Johansson H et al (2012) FRAX with and without BMD. Calcif Tissue Int 90:1–13PubMedCrossRef Kanis JA, McCloskey E, Johansson H et al (2012) FRAX with and without BMD. Calcif Tissue Int 90:1–13PubMedCrossRef
33.
Zurück zum Zitat Kanis JA, Johansson H, Ode'n A et al (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone (NY) 44:1049–1054CrossRef Kanis JA, Johansson H, Ode'n A et al (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone (NY) 44:1049–1054CrossRef
34.
Zurück zum Zitat McCloskey EV, Johansson H, Ode'n A et al (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double blind, placebo controlled randomised study. Osteoporos Int 20:811–818PubMedCrossRef McCloskey EV, Johansson H, Ode'n A et al (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double blind, placebo controlled randomised study. Osteoporos Int 20:811–818PubMedCrossRef
35.
Zurück zum Zitat McCloskey EV, Johansson H, Oden A et al (2012) Denosumab reduces the risk of all osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res 27(7):1480–1486PubMedCrossRef McCloskey EV, Johansson H, Oden A et al (2012) Denosumab reduces the risk of all osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res 27(7):1480–1486PubMedCrossRef
36.
Zurück zum Zitat Kanis JA, Oden A, Johansson H (2012) Pitfalls in the external validation of FRAX. Osteoporos Int 23(2):423–431PubMedCrossRef Kanis JA, Oden A, Johansson H (2012) Pitfalls in the external validation of FRAX. Osteoporos Int 23(2):423–431PubMedCrossRef
Metadaten
Titel
Possible FRAX-based intervention thresholds for a cohort of Chinese postmenopausal women
verfasst von
E. Cheung
C.-L. Cheung
A. W. C. Kung
K. C. B. Tan
Publikationsdatum
01.03.2014
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 3/2014
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-013-2553-9

Weitere Artikel der Ausgabe 3/2014

Osteoporosis International 3/2014 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.